Mr. Moss has been CFO since the formation of the Company in September 2015. Mr. Moss has founded, funded and taken public various companies in a variety of industries since 1995. Mr. Moss was a founding investor in Reliant Service Group LLC, which was acquired in 2015 by a leading private equity firm. Mr. Moss previously served as Managing Director, Corporate Finance for a New York-based securities firm, where he advised companies on corporate strategy, financings and business development. Prior to that, he served as Managing Partner at a Seattle-based venture capital firm. Mr. Moss holds an MBA from Rice University and a BA in Economics from the University of California, San Diego.

Prof. Lowdell has been a Chief Scientific Officer and Chief Manufacturing Officer since the formation of the Company in September 2015. Prof. Lowdell is Professor of Cell and Tissue Therapy at University College London, where he has led a translational immunotherapy group since 1994. Since February 2009, Prof. Lowdell has also been Director of Cellular Therapy at the Royal Free London NHS Foundation Trust. He received his PhD in clinical immunology from London Hospital Medical College, University of London in 1992 and is a qualified immunopathologist.

Dr. Barnum is the Head of Neuroscience at INmune Bio, Inc. Dr. Barnum is a neuroimmunologist with broad expertise across neurodegenerative and psychiatric diseases holding multiple positions in academia and industry, including Emory University, FPRT Bio., SonosBio, and most recently Takeda Pharmaceuticals. His focus has been on translating inflammatory therapies into clinical treatments for neurologic diseases using a biomarker-directed approach. Dr. Barnum has been working with XPro1595 for more than a decade, first at Emory University with Dr. Malú Tansey and subsequently as a consultant for FPRT Bio., Inc. and INmune Bio, before joining INmune Bio full time in 2018. Dr. Barnum’s research has been supported by NIH, The Michael J Fox Foundation, and the Alzheimer’s Association. He received his PhD in Neuroscience from Binghamton University.

Mr. Schoonover is our in-house counsel, primarily focused on developing intellectual property rights for the Company, as well as managing various licenses and other agreements. Mr. Schoonover has over ten years of experience building and monetizing intellectual property portfolios. His experience also includes multiple transactions, including a recent nine-figure acquisition of a portfolio containing over 230 patent matters which Mr. Schoonover drafted and prosecuted. He received a JD from Western Sierra Law School and a BS in Chemical Physics from San Diego State University. Mr. Schoonover is a member of the State Bar of California and is licensed to practice before the United States Patent & Trademark Office, the Southern District of California and the 9th Circuit Court of Appeals.

Ms. Lehner is the Vice President of Clinical Operations at INmune Bio. She has spent over 22 years in the pharmaceutical industry both as an employee and a consultant working across pharma, biotech and contract research organizations. In her last position, Ms. Lehner oversaw a $400 million dollar book of business for a long-term strategic partnership. Ms. Lehner holds an MS from the Temple University School of Pharmacy and a BA in Neuroscience from the University of Delaware and has been a certified PMP since 2011.

Mr. Ellspermann is our Interim Chief Financial Officer.  Prior to Mr. Ellspermann’s appointment as our Interim Chief Financial Officer, Mr. Ellspermann served as our Controller and VP of Finance since June 2019. Mr. Ellspermann possesses nearly 30 years of financial management experience at public and private companies. Prior to joining us, Mr. Ellspermann was Senior Accounting Manager at Artivest, an alternative investments company. He is a certified public accountant in the State of Texas and previously served as a Senior Audit Manager at Ernst & Young. He holds a BS in Accounting from Purdue University.